Literature DB >> 8499854

Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance?

H A Davies1, L Lennard, J S Lilleyman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8499854      PMCID： PMC1677595          DOI： 10.1136/bmj.306.6887.1239

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Applications of LhRh agonists against a wide range of gynecologic cancers.

Authors:  H W Bruckner; B T Motwani
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

2.  Compliance of pediatric and adolescent cancer patients.

Authors:  C K Tebbi; K M Cummings; M A Zevon; L Smith; M Richards; J Mallon
Journal:  Cancer       Date:  1986-09-01       Impact factor: 6.860

3.  A reliable method for evaluating drug compliance in children with cancer.

Authors:  S D Smith; D Rosen; R C Trueworthy; J T Lowman
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

4.  High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample.

Authors:  L Lennard; H J Singleton
Journal:  J Chromatogr       Date:  1992-11-27

5.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.

Authors:  L Lennard; J S Lilleyman; J Van Loon; R M Weinshilboum
Journal:  Lancet       Date:  1990-07-28       Impact factor: 79.321
  5 in total
  23 in total

Review 1.  Therapeutic trials in childhood ALL: what's their future?

Authors:  O B Eden
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

Review 2.  Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.

Authors:  Alan V Boddy
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

3.  Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study.

Authors:  Wendy Landier; Yanjun Chen; Lindsey Hageman; Heeyoung Kim; Bruce C Bostrom; Jacqueline N Casillas; David S Dickens; William E Evans; Kelly W Maloney; Leo Mascarenhas; A Kim Ritchey; Amanda M Termuhlen; William L Carroll; Mary V Relling; F Lennie Wong; Smita Bhatia
Journal:  Blood       Date:  2017-02-02       Impact factor: 22.113

Review 4.  Treatment of childhood asthma. Options and rationale for inhaled therapy.

Authors:  C V Powell; M L Everard
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

5.  Non-compliance with oral chemotherapy in childhood leukaemia.

Authors:  J S Lilleyman; L Lennard
Journal:  BMJ       Date:  1996-11-16

6.  Maintenance treatment and shared care in lymphoblastic leukaemia.

Authors:  J M Chessells
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

Review 7.  Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes.

Authors:  Saro H Armenian; Wendy Landier; Melissa M Hudson; Leslie L Robison; Smita Bhatia
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.

Authors:  S Wright; D S Sanders; A J Lobo; L Lennard
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  Malnutrition as a prognostic factor in lymphoblastic leukaemia: a multivariate analysis.

Authors:  M B Viana; M Murao; G Ramos; H M Oliveira; R I de Carvalho; M de Bastos; E A Colosimo; W S Silvestrini
Journal:  Arch Dis Child       Date:  1994-10       Impact factor: 3.791

10.  Clinical and laboratory evaluation of compliance in acute lymphoblastic leukaemia.

Authors:  B M de Oliveira; M B Viana; C L Zani; A J Romanha
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.